However, to improve the targeted delivery of GCV as an efflux inhibitor into the cancer cells, the utilization of cancer cell overexpressing GCV transporters, such as MATE1, MATE2-K, OAT1, OAT2, OCT1, and EEG1/ENBT1, is recommended to be explored. The gene discussed is SLC22A7; the disease is cancer.